Will We Be Able to “Cure” Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?
- 31 October 2008
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 54 (4) , 712-714
- https://doi.org/10.1016/j.eururo.2008.06.082
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Update on the Medical Treatment of Metastatic Renal Cell CarcinomaEuropean Urology, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell CarcinomaEuropean Urology, 2007
- Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosisCancer, 2007
- Renal Cell Carcinoma GuidelineEuropean Urology, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007